The study was designed to evaluate the medical relevance of total homocysteine (tHcy), total antioxidant capacity (TAC), and malondialdehyde (MDA) before and after chemotherapy for women with breast cancer (BRCA). Blood samples were taken from Oncology Unit in Merjian Teaching hospital in Hilla city (Iraq). Sixty patients suffering from breast cancer (BRCA) were enrolled in this study, and twenty-one apparently healthy subjects were considered as a control group control. We found that significantly increased lipid peroxidation, measured as MDA, was demonstrated in the serum of BRCA patients who were not taken any medication was higher than in the control group (P<0.01) were (25±15) nmol/ml of MDA levels in BRCA patient and (14.5±7.9) nmol/ml of MDA levels in healthy controls. We found that treatment by chemotherapy resulted in a significant increase in MDA levels when compared with MDA levels in patients who were not taken any medication. The tHcy level in BRCA patients before and after treatment were changed. In addition, it is found that the mean serum TAC levels in BRCA patients were significantly less than in the control group. Moreover, a positive correlation was observed between the activity of chemotherapy and MDA levels in the patient and the same correlation between tHcy levels and TAC levels while a negative correlation was observed between TAC levels with MDA levels in the patient group.

• MeSH
• Antioxidants MeSH
• Enzyme-Linked Immunosorbent Assay methods   MeSH
• Drug Therapy MeSH
• Homocysteine analysis   MeSH
• Humans MeSH
• Malondialdehyde analysis   MeSH
• Breast Neoplasms * drug therapy   pathology   MeSH
• Oxidative Stress drug effects   MeSH
• Lipid Peroxidation MeSH
• Check Tag
• Humans MeSH
• Female MeSH
• Publication type
• Clinical Study MeSH

Homocysteínový konsenzus odráža súčasné poznanie, že homocysteín (HCY) je pravdepodobnejšie rizikový marker ako faktor a paušálna liečba hyperhomocysteínémie neprináša očakávané zníženie morbidity a mortality kardiovaskulárnych ochorení. Panel odborníkov zastáva nasledujúce stanovisko do praxe pre liečbu a prevenciu kardiovaskulárnych ochorení: A. Paušálna terapeutická intervencia podľa súčasných poznatkov EBM nie je paušálne indikovaná.B. Paušálny skríning homocysteínu neprináša klinický prínos pre všeobecnú populáciu ani pre pacientov s kardiovaskulárnymi ochoreniami. Preventívne podávanie multivitamínov skupiny B pre zníženie hladiny homocysteínu podľa doterajších vedomostí založených na EBM vo všeobecnej populácii nemá podporu. Populačný skríning nie je indikovaný – trieda odporučení III, úroveň dôkazov IA. Terapeutické podávanie multivitamínov skupiny B pre zníženie hladiny homocysteínu podľa doterajších vedomostí zalo­žených na EBM v populácii pacientov v sekundárnej i terciárnej prevencii nemá význam. Populačný skríning nie je indikovaný – trieda odporučení III, úroveň dôkazov A. Nebol dostatočne preskúmaný prínos stanovenia HCY pri rozhodovaní o začatí antihypertenzívnej alebo hypolipidemickej liečby. Populačný skríning nie je indikovaný, iba vyšetrenie u individuálneho pacienta – trieda odporučení IIb, úroveň dôkazov A.

Homocysteine consensus reflects current knowledge that homocysteine is rather a risk marker then a factor and treatment of hyperhomocysteinemia does not reduce cardiovascular morbidity and mortality. Panel of experts state this position to approach cardiovascular prevention and treatment in praxis.A. General therapeutic intervention is not generally indicated based on current EBM data. B. General screening of homocysteine is not clinically beneficial in both general population and in patients with cardiovascular disease. Preventive administration of B group vitamins to reduce plasma homocysteine level in general population is not supported based on current EBM data. Population screening is not indicated – class III, level A. Therapeutic administration of B group vitamins to reduce plasma homocysteine level in patients in secondary or tertiary prevention is not supported based on current EBM data. Population screening is not indicated – class III, level A. There are no sufficient data on effect of measuring homocysteine on decision to start treating hypertension or dyslipidemias. Population screening is not indicated, only individual patients ́ examination – class IIb, level A.

• MeSH
• Homocysteine * analysis   blood   MeSH
• Cardiovascular Diseases * prevention & control   MeSH
• Humans MeSH
• Mass Screening MeSH
• Vitamin B Complex therapeutic use   MeSH
• Check Tag
• Humans MeSH
• Publication type
• Practice Guideline MeSH

Za účelem objektivizace změn hladin metabolomu neurosteroidů u dospělých klientů po komplexní lázeňské léčebně rehabilitační péči navázaly v roce 2017 vzájemnou spolupráci Endokrinologický ústav v Praze a Priessnitzovy léčebné lázně a.s. v Jeseníku. Autoři prezentují soubor 70 probandů, kteří absolvovali při nástupu a dimisi baterii klinických a laboratorních vyšetření. První výsledky změn metabolomu neurosteroidů, kineziologického vyšetření diagnostickou části Computer Kinesiology a výsledky Knoblochova dotazníku sebeposuzovací škály N-5 ukazují jednoznačně efekt léčení v lázních.

The Endocrinological Institute in Prague established the cooperation with in Priessnitz's spa a.s. in Jesenik intention to objectify changes in neurosteroid metabolomic biomarkers levels in adult clients after spa treatment, in 2017. The authors present a set of 70 probands. The first results of changes in the levels of neurosteroids, serotonin and homocysteine metabolite clearly demonstrate the effect of treatment in the spa. The kinesiological examination of the diagnostic part of Computer Kinesiology and the numeric outputs of Knobloch questionnaire (N-5 self- -judging scale) correlate with endocrinological results.

• Keywords
• Knoblochův dotazník N-5,
• MeSH
• Balneology * MeSH
• Adult MeSH
• Patient Reported Outcome Measures MeSH
• Outcome Assessment, Health Care MeSH
• Homocysteine analysis   blood   MeSH
• Kinesiology, Applied methods   MeSH
• Clinical Studies as Topic MeSH
• Clinical Laboratory Techniques methods   MeSH
• Middle Aged MeSH
• Humans MeSH
• Neurotransmitter Agents * analysis   blood   metabolism   MeSH
• Surveys and Questionnaires MeSH
• Aged MeSH
• Serotonin analysis   blood   MeSH
• Treatment Outcome MeSH
• Check Tag
• Adult MeSH
• Middle Aged MeSH
• Humans MeSH
• Male MeSH
• Aged MeSH
• Female MeSH
• Publication type
• Research Support, Non-U.S. Gov't MeSH

The aims of this study were to determine concentrations of total homocysteine, cysteine, cysteinylglycine and glutathione in spermatozoa, seminal fluid and blood plasma and to analyse their relationships with sperm parameters. For this reason, a new highly effective method of spermatozoa lysis was developed, using methanol, freezing and subsequent thawing in ultrasonic bath. An HPLC-FD assay was conducted on thiols concentrations in lysed spermatozoa, seminal fluid and blood plasma. Concentrations of thiols in spermatozoa were significantly lower in men with normozoospermia than in samples with pathological semen parameters. Statistical analysis found significant correlations between thiol concentrations in spermatozoa and semen parameters, while the same analysis with thiol concentrations in seminal fluid was substantially less powerful. Only cysteinylglycine concentrations in seminal fluid significantly correlated with pathological semen parameters. No significant differences or correlations were found with blood plasma concentrations.

• MeSH
• Adult MeSH
• Cell Fractionation methods   MeSH
• Homocysteine analysis   blood   MeSH
• Intracellular Space chemistry   MeSH
• Middle Aged MeSH
• Humans MeSH
• Adolescent MeSH
• Infertility, Male blood   metabolism   MeSH
• Semen chemistry   MeSH
• Spermatozoa chemistry   ultrastructure   MeSH
• Sulfhydryl Compounds analysis   blood   MeSH
• Check Tag
• Adult MeSH
• Middle Aged MeSH
• Humans MeSH
• Adolescent MeSH
• Male MeSH
• Publication type
• Journal Article MeSH

The HPLC method with coulochemical detection, used for the determination of selected aminothiol compounds (homocysteine, cysteine, reduced glutathione, methionine) in human plasma after quercetin supplementation by consuming cereal onion biscuits, was optimized. The effects of changes of organic modifier (acetonitrile and methanol in phosphate buffer) in the mobile phase and the pH value of the mobile phase on the retention and separation factors were studied. According to the results obtained, mobile phase containing 6 % acetonitrile (v /v) in 50 mmol L–1 sodium dihydrogen phosphate solution at pH 2.6 was found to be the most suitable for the separation of selected compounds. The method was validated with respect to linearity, precision, and accuracy. Results showed that the method was sufficiently reliable, sensitive, and suitable for application to real plasma samples in clinical or epidemiological studies. Results of the pilot study pointed to the fact that the consumption of onion biscuits (with increased content of quercetine) and simultaneous drinking of green tea during two months caused decrease of homocysteine level by about 18 %. However, there were no simple correlations between quercetin and investigated parameters observed.

• MeSH
• Cysteine analysis   blood   MeSH
• Functional Food utilization   MeSH
• Glutathione analysis   blood   MeSH
• Homocysteine * analysis   blood   MeSH
• Clinical Studies as Topic MeSH
• Plasma chemistry   MeSH
• Humans MeSH
• Blood Specimen Collection MeSH
• Reproducibility of Results MeSH
• Chromatography, High Pressure Liquid * utilization   MeSH
• Check Tag
• Humans MeSH
• Publication type
• Research Support, Non-U.S. Gov't MeSH

• MeSH
• Alzheimer Disease * diagnosis   genetics   blood   MeSH
• Biomarkers blood   MeSH
• Genetic Techniques MeSH
• Homocysteine analysis   blood   MeSH
• Clinical Studies as Topic MeSH
• Middle Aged MeSH
• Humans MeSH
• Polymorphism, Genetic MeSH
• Aged, 80 and over MeSH
• Aged MeSH
• Check Tag
• Middle Aged MeSH
• Humans MeSH
• Aged, 80 and over MeSH
• Aged MeSH
• Publication type
• Research Support, Non-U.S. Gov't MeSH

Přebytečný mozkomíšní mok (CSF) je odváděn neurochirurgicky zavedením drenážního systému. Odstraněním přebytečného CSF se normalizuje intrakraniální tlak a pacient se dostává do subjektivně dobrého stavu. Odvod CSF se provádí buď nárazově při akutním stavu, nebo kontinuálně zavedením tzv. shuntu, který odvádí přebytečnou tekutinu nejčastěji do dutiny břišní. V takto získaném CSF a v séru budeme analyzovat jak klinické ukazatele, tak vybrané biochemické a hormonální parametry. Na základě těchto analýz sepokusíme zjistit důvod rozvoje mentálních poruch u těchto pacientů, které vznikají v relativně krátkém časovém úseku od operace a prvotního výrazného zlepšení stavu. Na základě předešlých zkušeností s rozlišením Alzheimerovy demence od demence vaskulární se pokusíme pomocí vytipovaných laboratorních parametrů vypracovat matematický predikční model, který by přispěl k včasnému odhalení tohoto fatálního zvratu u pacientů trpících hydrocefalem.; Selected hormonal and other biochemical parameters in cerebrospinal fluid and serum, along with clinical status will be followed in patients with hydrocephalus treated neurosurgically by sucking off and subsequent channelling an excessive fluid into abdominal cavity. Taking advantage of non-invasive sampling after introduction of shunt and of the aformentioned analyses, we will attempt to find out, why in the most patients after initial improvement the dementia is developed, most frequently of Alzheimer´s type. Following our previous experience enabling us to distinguish Alzheimer´s disease from vascular dementia on the base of chosen laboratory parameters, we are going to establish a predictive mathematical model which would contribute to an early disclosure, why such a fatal reversion occurs in these patients.

• MeSH
• Aldosterone analysis   MeSH
• Dehydroepiandrosterone analysis   MeSH
• Dehydroepiandrosterone Sulfate analysis   MeSH
• Drainage MeSH
• Homocysteine analysis   MeSH
• Hydrocortisone analysis   MeSH
• Disease Management MeSH
• Metabolomics MeSH
• Cerebrospinal Fluid MeSH
• Neurodegenerative Diseases diagnosis   MeSH
• Neurotransmitter Agents diagnostic use   MeSH
• Hydrocephalus, Normal Pressure diagnosis   physiopathology   therapy   MeSH
• Prognosis MeSH
• Cerebrospinal Fluid Shunts MeSH
• Spinal Puncture MeSH
• Tandem Mass Spectrometry MeSH
• Models, Theoretical MeSH
• Chromatography, High Pressure Liquid MeSH

• Conspectus
• Fyziologie člověka a srovnávací fyziologie
• NML Fields
• endokrinologie
• neurologie
• NML Publication type
• závěrečné zprávy o řešení grantu IGA MZ ČR

• MeSH
• Extracellular Signal-Regulated MAP Kinases * analysis   MeSH
• Histological Techniques MeSH
• Homocysteine * analysis   administration & dosage   adverse effects   MeSH
• Hyperhomocysteinemia * chemically induced   physiopathology   MeSH
• Myocardial Infarction * etiology   MeSH
• Data Interpretation, Statistical MeSH
• Myocytes, Cardiac * physiology   pathology   MeSH
• Mathematical Computing MeSH
• Mitogen-Activated Protein Kinase Kinases * analysis   MeSH
• Rats, Wistar MeSH
• Heart physiology   physiopathology   MeSH
• Blotting, Western methods   utilization   MeSH
• Animals MeSH
• Check Tag
• Male MeSH
• Animals MeSH
• Publication type
• Research Support, Non-U.S. Gov't MeSH

Homocystein je intermediárním produktem metabolismu methioninu. Jeho koncentrace v organismu je kontrolována cestou remetylace a transsulfurace. Nedostatek či snížená funkce enzymů a kofaktorů v těchto procesech pak může vyústit v hyperhomocysteinemii. Vzácná vrozená porucha homocystinurie se vyznačuje extrémními hodnotami homocysteinu a vede k arteriálním i žilním trombózám v mladém věku. Homocystein je tedy považován za rizikový faktor cévních nemocí. Hodnota homocysteinu je ovlivněna mnoha faktory, jak genetickými, tak i vlivem prostředí. Mírná hyperhomocysteinemie je poměrně častá. Role homocysteinu v žilní tromboembolické nemoci (TEN) byla poněkud méně studována než u tepenných onemocnění a v současné době se jeví jako poněkud kontroverzní. In vitro lze prokázat mnohočetné protrombotické účinky homocysteinu. Výsledky epidemiologických studií však nejsou zcela jednoznačné. Většina z nich prokazuje asociaci hyperhomocysteinemie s žilní TEN, ovšem poměrně slabou, a navíc mnohem méně vyjádřenou ve studiích prospektivních než retrospektivních. Není zcela jasné, je-li elevace homocysteinu příčinou tromboembolické příhody či naopak jejím důsledkem. Je také možné, že hyperhomocysteinemie hraje roli v patogenezi žilní trombózy jen jako přídatný rizikový faktor v přítomnosti jiných trombofilií. Existují však i data potvrzující hyperhomocysteinemii jako rizikový faktor recidivy TEN. Několik menších studií popsalo také souvislost hyperhomocysteinemie s trombózou v neobvyklé lokalizaci. Koncentraci homocysteinu lze snížit suplementací vitaminů, především kyseliny listové a také vitaminu B12. Příznivý efekt snížení hodnoty v primární i sekundární prevenci TEN však dosud přesvědčivě prokázán nebyl. V současné době tedy není dostatek důkazů podporujících nutnost vyšetřování koncentrace homocysteinu u pacientů s žilní TEN ani potvrzujících prospěšnost suplementace vitaminy v případě mírné či střední hyperhomocysteinemie. Takováto diagnostika a léčba by proto měla být prováděna jen v selektovaných případech.

Homocysteine is an intermediary product of methionine metabolism. The level of homocysteine is controlled by two pathways – remethylation and transsulphuration. Elevated homocysteine level may result from deficiency or impaired function of enzymes and cofactors in these pathways. Homocystinuria is a rare genetic disease with extreme hyperhomocysteinemia and is associated with the occurrence of arterial and venous thrombotic events at young age. Therefore, homocysteine has been considered as a risk factor for vascular diseases. Plasma homocysteine level is influenced by many factors, genetic as well as environmental. Mild hyperhomocysteinemia is quite common. The role of homocysteine in venous thrombosis has been studied less extensively than its role in arterial diseases and nowadays it seems quite controversial. In vitro, it is possible to demonstrate multiple prothrombotic action of homocysteine. However, the results of epidemiologic studies are not so clear. Most of them found an association of hyperhomocysteinemia with venous thromboembolism (VTE) but the association was quite weak and moreover, it was much weaker in prospective than in retrospective studies. It is not quite clear whether elevated homocysteine level is the cause of thromboembolic event or the consequence of it. It is also possible that hyperhomocys-teinemia plays a role in the pathogenesis of VTE only as an additional risk factor in the presence of other thrombophilic disorders. However, some data confirm hyperhomocysteinemia as a risk factor for recurrent VTE. Some smaller studies have also found association of hyperhomocysteinemia with venous thrombosis at unusual sites. Homocysteine level is possible to decrease by vitamin supplementation, especially with folic acid and vitamin B12. So far, the benefit of lowering homocysteine level in primary and secondary VTE prevention has not been clearly proven. Currently, there is not enough evidence to support the necessity of testing homocysteine level in VTE patients, neither is sufficient evidence of the benefit of vitamin supplementation in mild or moderate hyperhomocysteinemia. Therefore, such testing and supplementation should be performed only in selected cases.

• MeSH
• Homocysteine analysis   metabolism   drug effects   MeSH
• Hyperhomocysteinemia * genetics   metabolism   physiopathology   prevention & control   MeSH
• Humans MeSH
• Risk Factors MeSH
• Vitamin B 12 administration & dosage   MeSH
• Vitamin B 6 administration & dosage   MeSH
• Venous Thromboembolism * epidemiology   etiology   metabolism   prevention & control   MeSH
• Check Tag
• Humans MeSH
• Publication type
• Research Support, Non-U.S. Gov't MeSH
• Review MeSH

We optimized and validated a rapid and sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the quantification of six metabolites of homocysteine metabolism: homocysteine, methionine, cysteine, S-adenosylmethionine, S-adenosylhomocysteine and betaine. The detection limits for these metabolites were in the nanomolar range, and the intra- and inter-day precisions were lower than 20% of the relative standard deviations. The method was specifically designed for the determination of the intracellular concentrations of the metabolites in cultured cells. To study the role of betaine-homocysteine S-methyltransferase (BHMT), HepG2 cells and HepG2 cells that were stably transfected with BHMT ((BHMT) HepG2) were treated with homocysteine or with a specific inhibitor of BHMT, and metabolite levels were subsequently measured. Severely compromised methyl group metabolism in the HepG2 cells, which is typical of cancer-derived cells, prevented clear evaluation of the changes caused by the external manipulations of homocysteine metabolism. However, the ease of handling these cells and the almost unlimited source of experimental material supplied by cells in permanent culture allowed us to develop a reliable methodology. The precautions concerning intracellular metabolite determinations using LC-MS/MS in cultured cells that are expressed in this work will have global validity for future metabolomics studies.

• MeSH
• Betaine-Homocysteine S-Methyltransferase metabolism   MeSH
• Hep G2 Cells MeSH
• Chromatography, Liquid MeSH
• Homocysteine analogs & derivatives   analysis   chemistry   metabolism   MeSH
• Calibration MeSH
• Humans MeSH
• Linear Models MeSH
• Reproducibility of Results MeSH
• Sensitivity and Specificity MeSH
• Tandem Mass Spectrometry MeSH
• Check Tag
• Humans MeSH
• Publication type
• Journal Article MeSH
• Research Support, Non-U.S. Gov't MeSH